Adarx Pharmaceuticals reportedly seeks up to $371.9 million in US IPO
Bloomberg describes Adarx as a late-stage developer of gene therapies seeking a US initial public offering.
TLDR
Adarx Pharmaceuticals is seeking to raise as much as $371.9 million in a US initial public offering, Bloomberg reports. The company is a late-stage developer of gene therapies, according to the report.
Combined views
43.9K
1 Source, first seen 9d ago
6 likes2 comments4 saves4 reposts